Noonan Syndrome with Multiple Lentigines (NSML) — Comprehensive Research Report

Executive Summary

Noonan syndrome with multiple lentigines (NSML), historically known as LEOPARD syndrome, is a rare autosomal dominant RASopathy caused predominantly by loss-of-function/dominant-negative missense variants in PTPN11 (encoding the tyrosine phosphatase SHP2), with rarer causal variants in RAF1, BRAF, and MAP2K1. It is defined clinically by the acronym-derived features: multiple Lentigines, ECG conduction abnormalities, Ocular hypertelorism, Pulmonary valve stenosis, Abnormal genitalia, Retardation of growth, and sensorineural Deafness — though the name is now deprecated in favor of "Noonan syndrome with multiple lentigines" to reflect its position on the Noonan syndrome/RASopathy phenotypic continuum (GeneReviews, NBK1383).

1. Disease Information

Overview: NSML is a multisystem RASopathy presenting with progressive multiple lentigines, hypertrophic cardiomyopathy (HCM) and other cardiac defects, short stature, pectus deformity, characteristic facial dysmorphism, sensorineural hearing loss, and — in a subset — mild intellectual disability. It is mechanistically and phenotypically distinct from, yet overlapping with, classic Noonan syndrome (NS) and cardiofaciocutaneous syndrome (CFCS), together forming the RASopathy spectrum of RAS/MAPK pathway disorders.

Key identifiers: - OMIM: Phenotypic series PS151100 - #151100 — LEOPARD syndrome 1 (LPRD1), PTPN11 - #611554 — LEOPARD syndrome 2 (LPRD2), RAF1 - #613707 — LEOPARD syndrome 3 (LPRD3), BRAF - Orphanet: ORPHA:500 ("Leopard syndrome") - MONDO: MONDO:0007893 - ICD-10-CM: Q87.1 (Congenital malformation syndromes predominantly associated with short stature) - MeSH: LEOPARD Syndrome (D007925) - GeneReviews: NBK1383

Synonyms: LEOPARD syndrome; Lentiginosis profusa; Multiple lentigines syndrome; Cardiocutaneous syndrome; Capute syndrome; Noonan syndrome with multiple lentigines (current preferred term, per 2018 international RASopathy nomenclature consensus, reflecting recognition that the disorder is a subtype within the Noonan spectrum rather than a fully distinct entity).

Evidence basis: Information is derived from aggregated disease-level resources (OMIM, Orphanet, GeneReviews) built from case reports, case series (~150+ reported individuals, per GeneReviews), and cohort studies, rather than a large EHR-scale population. This is consistent with a genuinely rare condition without population-based prevalence data.

2. Etiology

Disease causal factors: NSML is caused by heterozygous germline pathogenic missense variants in one of four RAS/MAPK pathway genes. There is no environmental, infectious, or purely mechanistic etiology — this is a monogenic developmental signaling disorder.

Genetic causal factors (per GeneReviews NBK1383):

Foundational papers establishing PTPN11 as the major NSML gene: Digilio MC, et al. "Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene." Am J Hum Genet. 2002;71(2):389-394. PMID:12161596 — the paper that first showed distinct PTPN11 mutations (exon 8 and exon 13 "hotspots," e.g., Y279C, T468M) segregate specifically with the LEOPARD/NSML phenotype rather than classic NS.

RAF1 causal role: Pandit B, et al. "Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy." Nat Genet. 2007;39(8):1007-1012. PMID:17603483 — reported that of subjects with RAF1 mutations at two hotspots (mostly flanking Ser259, the 14-3-3 binding autoinhibitory residue), 95% developed HCM, versus ~18% background HCM prevalence in general NS.

Molecular mechanism distinction (critical for pathophysiology modeling): Unlike classic-NS-causing PTPN11 variants, which are activating (gain-of-function for SHP2 phosphatase activity, increasing RAS-MAPK flux), NSML-causing PTPN11 variants are catalytically inactivating and act as dominant-negatives — see Kontaridis MI, et al. "PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects." J Biol Chem. 2006;281(10):6785-6792. PMID:16377799: "LEOPARD syndrome mutants are catalytically defective and act as dominant negative mutations that interfere with growth factor/Erk-mitogen-activated protein kinase-mediated signaling." This distinction (LOF/dominant-negative SHP2 in NSML vs. GOF SHP2 in NS) is the central mechanistic bifurcation of the PTPN11-associated RASopathies, despite both converging on paradoxically hyperactive ERK signaling in specific tissue contexts (notably heart), likely via SHP2-independent scaffolding/PZR-mediated compensatory mechanisms.

Risk factors: - Genetic: Autosomal dominant inheritance — an affected parent confers 50% transmission risk per child. Most cases are simplex (presumed de novo), though the proportion of de novo cases is not firmly established (GeneReviews). - Environmental: None established. This is a purely germline monogenic disorder; there is no known toxin, occupational, or infectious contribution. - Age/sex: No sex predilection reported. Onset is congenital/prenatal at the molecular level; clinical features (especially lentigines) accumulate progressively through childhood.

Protective factors: None specifically established for disease occurrence (it is fully penetrant once the variant is inherited/arises de novo). Notably, at the phenotypic/metabolic level, the LEOPARD-associated SHP2 mutation has been shown in mouse models to confer a protective metabolic phenotype (see Mechanism section) — an unusual "trade-off" finding.

Gene-environment interactions: Not established; NSML severity and expressivity appear to be driven by allelic/genotype effects (which gene, which specific residue) rather than documented environmental modifiers.

3. Phenotypes

All phenotype frequencies below are from GeneReviews (NBK1383) unless otherwise cited; HPO term suggestions are given per phenotype.

Cutaneous

• Multiple lentigines (nearly all affected individuals; the defining/eponymous feature) — flat, black-brown macules 2–5 mm concentrated on face, neck, and upper trunk, sparing mucosa; typically absent at birth, appearing around age 4–5 years and increasing to the thousands by puberty. HP:0001065 (Lentigines).
• Café-au-lait macules (70–80%), which may precede lentigines. HP:0000957 (Café-au-lait spot).
• Nevi, may also occur.

Cardiovascular

• Cardiac defects overall (~85% of patients).
• Hypertrophic cardiomyopathy (HCM) — the dominant cardiac feature, ~70–80% of those with cardiac defects (frequently left-ventricular, sometimes progressive, often presenting in infancy). HP:0001639 (Hypertrophic cardiomyopathy).
• Pulmonary valve stenosis (~20–25%). HP:0001642 (Pulmonic stenosis).
• ECG/conduction abnormalities (~25%) — including left-axis deviation, abnormal Q waves, arrhythmia. HP:0003115 (Abnormal EKG).
• Gene-specific note: RAF1-mutated NSML shows near-universal (~95%) HCM association (Pandit et al. 2007, PMID:17603483), making RAF1-NSML one of the strongest known monogenic HCM risk genotypes.

Growth

• Short stature — >50% significantly affected, most individuals below 25th percentile. Onset is typically postnatal, becoming apparent in childhood. HP:0004322 (Short stature).

Skeletal

• Pectus deformity (excavatum/carinatum), a cardinal diagnostic feature. HP:0000766/HP:0000768.

Craniofacial

• Dysmorphic facial features (nearly all): widely spaced eyes/ocular hypertelorism, ptosis, low-set posteriorly rotated ears, broad or webbed neck. HP:0000316 (Hypertelorism), HP:0000508 (Ptosis).

Genitourinary

• Cryptorchidism in ~30–33% of affected males. HP:0000028.
• Renal anomalies less common but part of surveillance recommendations.

Neurologic / Sensory

• Sensorineural hearing loss (~15–20%), which can be congenital and is sometimes the presenting feature. HP:0000407 (Sensorineural hearing loss).
• Mild intellectual disability / learning difficulties in ~30% (typically mild). HP:0001256 (Intellectual disability, mild).
• Autism-spectrum-related traits have also been studied comparatively between NS and NSML cohorts (Molecular Autism, 2025), suggesting overlapping neurodevelopmental profiles across RASopathies, though NSML-specific autism prevalence data remain limited.
• Occasional reports of seizures and, rarely, intracerebral hemorrhage in PTPN11-mutated NSML (case report, PMC7983560).

Oncologic (rare but notable)

• Elevated tumor predisposition has been reported in NSML/PTPN11-related RASopathies, including neuroblastoma, acute myeloid leukemia, and acute lymphoblastic leukemia; broader RASopathy literature reports solid tumors (rhabdomyosarcoma, neuroblastoma, bladder carcinoma) in ~15% of Noonan-spectrum patients by age 20, though NSML-specific tumor incidence figures are less precisely quantified than for classic juvenile myelomonocytic leukemia risk in NS.

Progression/course: Lentigines are absent at birth and accumulate over childhood/adolescence (progressive). HCM, if present, often manifests in infancy and can be progressive. Hearing loss and short stature are generally stable once established but require ongoing developmental/audiologic monitoring. Overall disease course is chronic and lifelong, non-remitting, with severity highly variable even within families (variable expressivity).

Quality of life impact: Cosmetic impact of lentigines can be psychosocially significant (visible facial/trunk pigmentation from childhood). Cardiac disease (HCM, arrhythmia risk) and hearing loss are the principal drivers of morbidity and long-term QoL burden; no NSML-specific EQ-5D/SF-36 data were identified in this search, but general RASopathy QoL literature emphasizes cardiac and neurodevelopmental domains as most impactful.

4. Genetic/Molecular Information

Causal genes (detailed):

Pathogenic variant characteristics: - Variant type: Overwhelmingly missense (single amino-acid substitutions), consistent with a requirement for a specific structural/functional perturbation rather than simple loss of the gene product (null alleles are not typically disease-causing in this manner). - PTPN11 hotspots: Classic NSML-associated residues cluster in the PTP catalytic domain, notably Y279C and T468M (together accounting for the majority of PTPN11-NSML cases), plus others including A461T, G464A, Q506P, Q510E/P, T507K. These are largely non-overlapping with the N-SH2/PTP-interface hotspots that cause classic gain-of-function NS (e.g., N308D, D61G). - Variant classification: ClinVar lists numerous PTPN11 variants specifically annotated "Pathogenic"/"Likely pathogenic" for "Noonan syndrome with multiple lentigines" (e.g., NM_002834.5:c.836A>G p.Tyr279Cys; c.1403C>T p.Thr468Met — both classic NSML hotspot alleles). - RAF1 hotspot: Predominantly substitutions flanking Ser259 (a 14-3-3 binding/autoinhibitory residue), which when mutated relieve autoinhibition → constitutive kinase activation (Pandit et al. 2007, PMID:17603483). - Germline vs somatic: NSML variants are constitutional/germline (heritable), distinguishing them from the somatic PTPN11 mutations found in juvenile myelomonocytic leukemia and other sporadic cancers, which — notably — are typically the activating class of PTPN11 mutation, not the NSML dominant-negative class. - Functional consequence: PTPN11-NSML variants → loss of SHP2 catalytic (phosphatase) activity with dominant-negative interference of normal SHP2 signaling (PMID:16377799). RAF1/BRAF/MAP2K1-NSML variants → classic gain-of-function kinase activation, paralleling their mechanism in classic NS. - Allele frequency: These are rare, highly penetrant pathogenic alleles essentially absent from population databases (gnomAD) consistent with disease severity and predominantly de novo/small-pedigree segregation.

Modifier genes: No well-established modifier genes for NSML severity have been robustly identified in the literature reviewed; expressivity varies substantially even within PTPN11-Y279C or T468M carriers, suggesting stochastic or background-genetic modulation not yet mapped.

Epigenetic information: No NSML-specific DNA methylation/chromatin studies were identified in this search; SHP2 broadly participates in growth-factor receptor signal transduction rather than direct epigenetic regulation, though downstream ERK activity can influence chromatin-modifying enzyme activity indirectly.

Chromosomal abnormalities: None — NSML is caused by point mutations, not large structural/copy-number chromosomal changes.

5. Environmental Information

No environmental toxins, radiation, pollutants, occupational exposures, lifestyle factors, or infectious agents are implicated in NSML causation — it is a purely monogenic germline disorder. This section is not applicable beyond noting the absence of such associations in the literature reviewed.

6. Mechanism / Pathophysiology

Overview causal chain: Germline PTPN11 (or RAF1/BRAF/MAP2K1) missense variant → altered RAS/MAPK (ERK) pathway signal transduction (tissue-context-dependent gain vs. loss of specific signaling outputs) → aberrant developmental signaling in cardiac, craniofacial, melanocytic, growth-plate, and neural tissues → the multisystem NSML phenotype.

Molecular pathway: RAS-MAPK (RAS/RAF/MEK/ERK) signal transduction pathway — GO/KEGG: KEGG hsa04010 (MAPK signaling pathway); relevant GO biological process term GO:0007265 (Ras protein signal transduction) and GO:0038095 (Fc-epsilon receptor signaling pathway components feeding into ERK, where SHP2 also participates), plus GO:0004725 (protein tyrosine phosphatase activity) for SHP2's catalytic function.

SHP2/PTPN11-specific mechanism: SHP2 is a cytoplasmic non-receptor protein-tyrosine phosphatase that normally acts as a positive transducer of RTK (receptor tyrosine kinase)-RAS-ERK signaling in most contexts (its N-SH2 domain autoinhibits the PTP domain at baseline; growth-factor-induced phosphotyrosine binding to the SH2 domains opens the catalytic pocket). Classic NS mutations destabilize this autoinhibited conformation → constitutively open/active SHP2 → excess RAS-ERK flux. NSML mutations instead directly impair PTP catalytic activity (many cluster in/near the catalytic cleft) while still permitting normal SH2-mediated docking, producing a catalytically-dead but still-scaffolding SHP2 species that acts as a dominant-negative, sequestering binding partners and paradoxically causing tissue-specific hyperactivation of ERK in some contexts (e.g., developing heart) via PZR-dependent or other scaffold-mediated compensatory signaling (Kontaridis 2006, PMID:16377799; Lauriol et al., JCI 2016, PMID:27348588).

Cardiac hypertrophy mechanism (best-characterized organ pathophysiology): - Lauriol J, et al. "Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines." J Clin Invest. 2016;126(8):2989-3005. PMID:27348588 — showed using a knock-in Ptpn11^Y279C/+ mouse (NSML model) that HCM originates from aberrant SHP2 signaling in the developing endocardium; endothelial-specific expression of the NSML mutant SHP2 was sufficient to induce adult-onset cardiac hypertrophy, implicating a developmental-origin, tissue-autonomous endocardial signaling defect rather than a purely adult cardiomyocyte-intrinsic process. - Marin TM, et al. (PZR paper) "PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice." J Clin Invest. 2011 (cited via PubMed). PMID:24865967 — identifies PZR (a transmembrane SHP2-binding adaptor) as a convergence point coordinating both NS (GOF) and NSML (dominant-negative) SHP2 signaling in cardiac tissue across zebrafish and mouse models. - Marin TM, et al. "Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation." J Clin Invest. 2011;121(3):1026-1043. PMID:21339643 — demonstrated that NSML-associated PTPN11 mutant knock-in mice develop HCM via mTOR pathway hyperactivation downstream of the aberrant SHP2 signal, and that rapamycin (an mTOR inhibitor) reverses established cardiac hypertrophy — a key mechanistic and therapeutic-rationale finding, and one of the first proof-of-concept "mechanism-targeted therapy reverses RASopathy cardiomyopathy" studies. - Edouard T, et al./Kontaridis lab, JCI Insight, "Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines" — further elaborates the PZR-tyrosine-phosphorylation axis as necessary for NSML-associated cardiac hypertrophy.

Cellular processes involved: Aberrant cardiomyocyte/endocardial growth-factor signaling → hypertrophic cardiomyocyte growth program (mTOR/ERK hyperactivation); dysregulated melanocyte proliferation/pigment production underlying lentigo formation; abnormal chondrocyte/growth-plate signaling contributing to short stature; RAS-MAPK-dependent craniofacial neural crest/mesenchymal patterning defects producing dysmorphic facial features (consistent with the broader RASopathy craniofacial mechanism also seen in NS/CFCS).

Protein dysfunction: Loss-of-function (catalytic) combined with dominant-negative scaffolding retention for PTPN11-NSML SHP2; classic gain-of-function kinase activation for RAF1/BRAF/MAP2K1-NSML variants — see UniProt Q06124 (PTPN11/SHP2), P04049 (RAF1), P15056 (BRAF) for domain/structure annotations.

Metabolic changes: Notably, Tajan M, et al. "LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity." Proc Natl Acad Sci USA. 2014;111(42):E4494-E4503. PMID:25288766 — found that mice carrying the NSML-associated SHP2 mutation display reduced adiposity, resistance to diet-induced obesity, and improved carbohydrate metabolism, with impaired adipogenesis and increased energy expenditure. This is a striking, disease-relevant metabolic phenotype directly attributable to loss of catalytic SHP2 activity in adipose tissue, representing a rare example of a RASopathy mutation conferring a "beneficial" systemic metabolic trade-off alongside its pathogenic manifestations (relevant to HMDB/metabolomics framing).

Immune system involvement: Not a primary disease axis for NSML specifically (contrast with somatic activating PTPN11 mutations, which are strongly linked to myeloproliferative/leukemic disease via hematopoietic stem/progenitor cell effects — a related but mechanistically distinct PTPN11 disease axis, per the eLife 2022 HSPC inflammatory-response paper referenced in the broader PTPN11 literature).

Single-cell / advanced technologies: Endothelial/endocardial-lineage-restricted Cre-driver mouse studies (Lauriol 2016) represent the primary cell-type-resolved mechanistic dissection available; no human single-cell or spatial transcriptomic NSML-specific datasets were identified in this search.

Suggested GO/CL terms: - GO:0004725 — protein tyrosine phosphatase activity (SHP2 catalytic function) - GO:0007173 — epidermal growth factor receptor signaling pathway (upstream RTK input) - GO:0043408 — regulation of MAPK cascade - GO:0038095 — Fc-epsilon receptor signaling pathway (SHP2-relevant scaffold context) - CL:0000746 — cardiac muscle cell (myocyte hypertrophy) - CL:0002350 — endocardial cell (developmental origin of cardiac hypertrophy per Lauriol 2016) - CL:0000148 — melanocyte (lentigo formation) - CL:0000138 — chondrocyte (growth-plate/short-stature mechanism, by analogy to NS)

7. Anatomical Structures Affected

Organ level: - Primary: Heart (myocardium/endocardium — HCM, pulmonary valve, conduction system), skin (melanocytes — lentigines, café-au-lait), skeletal system (chest wall — pectus; growth plates — short stature), craniofacial skeleton/soft tissue, inner ear (cochlea — sensorineural hearing loss), gonads (testes — cryptorchidism). - Secondary: CNS (mild ID, rare seizures/hemorrhage), hematopoietic/lymphoid tissue (rare leukemia association), neural crest-derived tissues broadly (neuroblastoma risk). - Body systems: Cardiovascular, integumentary, musculoskeletal, endocrine/growth, auditory, genitourinary, nervous, and (rarely) hematologic/oncologic systems.

Tissue/cell level: Cardiomyocytes and endocardial cells (CL:0000746, CL:0002350); epidermal melanocytes (CL:0000148); growth-plate chondrocytes (CL:0000138); cochlear hair cells/spiral ganglion (sensorineural hearing loss mechanism, by analogy — CL:0000202 hair cell).

Subcellular level: Cytoplasmic signaling (SHP2 is cytosolic/membrane-proximal — GO:0005829 cytosol, GO:0005886 plasma membrane for RTK-proximal docking); nuclear ERK translocation for transcriptional output (GO:0005634).

UBERON localization: UBERON:0000948 (heart), UBERON:0002050 (embryonic heart tube/endocardium), UBERON:0002097 (skin), UBERON:0001911 (skin of face), UBERON:0002415 (thorax/chest wall — pectus), UBERON:0001846 (auditory receptor organ/cochlea — hearing loss), UBERON:0000473 (testis — cryptorchidism).

Lateralization: Not a laterality-defined disorder; findings are generally bilateral/symmetric (facial features, hearing loss when present) with the exception of asymmetric distribution of individual lentigines.

8. Temporal Development

• Onset: Congenital at the molecular/developmental level (a germline variant present from conception; cardiac and craniofacial developmental effects begin prenatally per the endocardial-origin HCM mechanism). Clinically apparent features emerge across a spectrum: cardiac defects can be detected prenatally/neonatally; lentigines are characteristically absent at birth, emerging around age 4–5 years; short stature becomes apparent through childhood; hearing loss may be congenital or emerge later.
• Onset pattern: Insidious/progressive for pigmentary and growth features; can be acute/critical in infancy for severe neonatal HCM presentations (rare RAF1-mutant cases reported with severe neonatal HCM).
• Progression: Lentigines progressively increase in number from childhood through puberty (thousands by adolescence). HCM, when present, is often progressive, particularly in RAF1-mutated cases, and can require escalating cardiac management. Short stature and craniofacial features are generally stable once fully expressed in adulthood.
• Disease course pattern: Chronic, lifelong, generally non-remitting for the structural/pigmentary features; cardiac status may stabilize, progress, or (rarely, with mechanism-targeted therapy such as MEK inhibition) improve.
• Critical periods: Prenatal/early postnatal cardiac development is a mechanistically critical window (per the endocardial-origin HCM data), suggesting early identification and cardiac surveillance are especially important in infancy.

9. Inheritance and Population

Epidemiology: Population prevalence is not precisely established — NSML is considered a rare condition even among RASopathies; GeneReviews notes ~150+ individuals reported in the literature to date. For context, classic Noonan syndrome (the broader RASopathy family) occurs in ~1:1,000–1:2,500 live births, but NSML is substantially rarer than NS overall.

Inheritance pattern: Autosomal dominant (all four causal genes — PTPN11, RAF1, BRAF, MAP2K1).

Penetrance: High/complete penetrance for the core phenotype in reported pedigrees, though expressivity is highly variable — even among relatives sharing the identical variant, severity of cardiac, cutaneous, and growth features differs substantially.

Genetic anticipation: Not a described feature (this is a missense-variant disorder, not a repeat-expansion disorder).

Germline mosaicism: Recognized as a mechanism for sibling recurrence in families where the proband's variant is presumed de novo — GeneReviews estimates sibling recurrence risk of ~1% in de novo cases, attributable to possible parental germline mosaicism.

Founder effects: No specific NSML founder population/mutation was identified in this search (contrast with some other RASopathy-adjacent conditions where specific founder alleles are described in isolated populations).

Consanguinity: Not a relevant risk factor, given the autosomal dominant (not recessive) mode of inheritance.

Population demographics: No specific ethnic or geographic enrichment was identified in the sources reviewed; reported cases span multiple populations and geographic regions (Italy, Korea, China, and others represented in the literature surveyed here).

Sex ratio: No sex predilection reported.

Age distribution: Diagnosed across the lifespan, from prenatal/neonatal (via cardiac findings and, increasingly, prenatal genetic testing) through adulthood; many cases are identified in childhood when lentigines and growth/cardiac features become apparent.

10. Diagnostics

Clinical diagnostic criteria (per GeneReviews/van der Burgt-style criteria): - Multiple lentigines plus 2 other cardinal features (cardiac abnormality; short stature; pectus deformity; dysmorphic facial features), OR - In the absence of lentigines: 3 cardinal features plus an affected first-degree relative.

Genetic testing: - Recommended approach: Given genetic heterogeneity, a multigene panel covering PTPN11, RAF1, BRAF, and MAP2K1 (and often the broader RASopathy/Noonan-spectrum gene panel to capture phenocopies) is the preferred first-tier test, per GeneReviews. - Single-gene testing: PTPN11 sequencing alone captures >95% of molecularly-confirmed cases and is a reasonable first step if resources are constrained, given the high prior probability. - Detection rate: Sequence analysis (Sanger or NGS) detects the causal variant in nearly 100% of cases with a variant in PTPN11 or RAF1 once a gene is targeted; large deletions/duplications are not a recognized mechanism (this is a missense-only disease mechanism). - WES/WGS: Useful when the multigene panel is non-diagnostic or when the phenotype is atypical/overlaps other RASopathies; exome-first strategies are increasingly used given the broader RASopathy differential. - Prenatal/preimplantation testing: Available once a familial pathogenic variant is identified.

Clinical/laboratory tests (non-genetic): - Echocardiogram — first-line for HCM/pulmonary stenosis detection; LOINC-coded structured echo reporting applicable. - ECG — for conduction abnormalities. - Audiology (audiometry) — for sensorineural hearing loss screening. - Ophthalmologic exam — for hypertelorism-associated or other ocular findings. - Renal ultrasound — part of baseline evaluation per GeneReviews surveillance. - Developmental/neuropsychological assessment — for intellectual disability/learning difficulties.

Differential diagnosis (critical for accurate curation, per GeneReviews): - Classic Noonan syndrome — NSML is distinguished primarily by the profuse pigmented lesions/lentigines, which NS typically lacks; molecular testing (LOF/dominant-negative vs GOF PTPN11 variant) is definitive. - Cardiofaciocutaneous syndrome (CFCS) — more severe intellectual disability, structural CNS anomalies, seizures, more extensive skin pathology than NSML. - Costello syndrome — another RASopathy on the differential, with its own distinct HRAS-driven features. - Turner syndrome — requires karyotype exclusion; Turner syndrome shows predominantly left-sided heart defects (coarctation, bicuspid aortic valve) rather than HCM. - Williams syndrome — requires 7q11.23 deletion testing to exclude. - Legius syndrome / NF1 — for café-au-lait-predominant presentations without lentigines/cardiac features.

Screening: No population-based newborn screening program exists for NSML (it is not amenable to biochemical newborn screening); identification is via clinical suspicion (cardiac finding, dermatologic finding) followed by targeted or panel genetic testing, or via cascade testing of relatives once a familial variant is known.

11. Outcome/Prognosis

Survival/mortality: No population-based survival statistics were identified in this search; prognosis is heavily dependent on the severity of the cardiac phenotype — severe, early-onset (especially RAF1-associated) HCM is the principal driver of morbidity/mortality risk, while individuals without significant cardiac involvement generally have a normal life expectancy.

Morbidity/complications: - Progressive/obstructive HCM can lead to heart failure, arrhythmia, and (in severe pediatric cases) need for advanced heart-failure therapies. - Sensorineural hearing loss can affect speech/language development if unaddressed. - Rare but reported complications include neuroblastoma, leukemia (AML/ALL), and — in isolated case reports — intracerebral hemorrhage in PTPN11-mutated individuals (PMC7983560). - Psychosocial morbidity from visible cutaneous lentiginosis.

Recovery potential / treatment response: Emerging mechanism-targeted therapy data (MEK inhibition — see Treatment section) show that cardiac hypertrophy can be pharmacologically reversed or ameliorated in some cases, a substantial shift from purely supportive management historically available.

Prognostic factors: Causal gene is a major prognostic determinant — RAF1-mutated NSML carries a markedly higher (~95%) risk of HCM than PTPN11-mutated NSML, making genotype an important prognostic/surveillance-intensity variable.

12. Treatment

Standard/supportive management (per GeneReviews): - Cardiac: Standard HCM management (beta-blockers, surveillance for outflow obstruction/arrhythmia, surgical septal myectomy in severe obstructive cases); standard management of structural defects (e.g., pulmonary valve stenosis — balloon valvuloplasty as needed). - Ophthalmologic: Management of eye anomalies/eye movement abnormalities. - Audiologic: Hearing aids/early intervention for sensorineural hearing loss. - Endocrine/growth: Growth hormone therapy may be contraindicated in individuals with hypertrophic cardiomyopathy (explicit GeneReviews caution) — an important genotype-informed prescribing constraint distinct from classic NS management, where GH therapy is more routinely considered. - Urologic: Standard management of cryptorchidism (orchiopexy). - Neurodevelopmental: Early intervention/educational support for developmental and learning issues; seizure management when present. - Dermatologic: Cosmetic/dermatologic management of lentigines is generally elective (no medical necessity), though psychosocial support may be warranted.

Emerging mechanism-targeted (MEK inhibitor) therapy — RASopathy-wide, actively being extended to NSML/HCM: - Trametinib (a selective, FDA-approved MEK1/2 inhibitor originally for melanoma) has shown efficacy in case reports and early trials for RASopathy-associated obstructive HCM, including RAF1-associated Noonan-spectrum cardiomyopathy — see "Treatment of RAF1-Related Obstructive Hypertrophic Cardiomyopathy by MEK Inhibition Using Trametinib" and "MEK Inhibition in a Newborn with RAF1-Associated Noonan Syndrome Ameliorates Hypertrophic Cardiomyopathy" (PMC8774485). - An active randomized clinical trial (NCT06555237, "MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies") is evaluating trametinib in children (age 0–18) with RAS-MAPK-pathway-confirmed HCM. - Mechanistically, this rationale is directly supported by the mouse-model literature above (Marin 2011, PMID:21339643 — mTOR inhibition with rapamycin reverses NSML-model HCM; and the broader RAS-MAPK hyperactivation-in-cardiac-tissue mechanism), even though the causal PTPN11-NSML lesion is a phosphatase loss-of-function — underscoring that downstream pathway output (not just the proximal lesion direction) determines therapeutic targetability. MAXO:0000647 (chemotherapy — closest generic action term; trametinib itself would be better captured via therapeutic_agent/NCIT/CHEBI rather than forcing into a chemotherapy action term) and a Pharmacotherapy (NCIT:C15986) treatment_term with therapeutic_agent bound to Trametinib (NCIT:C77908) would be the appropriate dismech-style annotation pattern. - Rapamycin/mTOR inhibitors — proof-of-concept reversal of HCM in the NSML mouse model (PMID:21339643) supports mTOR inhibition as an alternative/complementary mechanistic target, though clinical translation specifically in NSML patients is less advanced than for trametinib.

Surgical: Cardiac surgery (septal myectomy) for severe obstructive HCM; orchiopexy for cryptorchidism; standard pectus repair surgery when clinically indicated.

Suggested MAXO terms: - MAXO:0000011 — physical therapy (as needed for developmental support) - MAXO:0000004 — surgical procedure (cardiac/orchiopexy/pectus) - MAXO:0000079 — genetic counseling - MAXO:0000950 — supportive care

13. Prevention

Primary prevention: Not applicable in the traditional sense (this is a de novo/inherited germline genetic disorder, not preventable via risk-factor modification); however, family planning options (preimplantation genetic testing, prenatal diagnosis) constitute the primary "prevention" lever once a familial pathogenic variant is known.

Secondary prevention (early detection): Early echocardiographic screening in infants of affected parents (or those presenting with suggestive features) allows early HCM detection before symptomatic heart failure develops; early audiologic screening supports early intervention for hearing loss.

Genetic counseling: Central to NSML management — counseling on 50% transmission risk to offspring of an affected individual, ~1% sibling recurrence risk in de novo cases (germline mosaicism), variable expressivity (a parent with mild disease can have a more severely affected child, and vice versa), and reproductive options (prenatal testing, preimplantation genetic testing). GeneReviews and NSGC-aligned genetic counseling resources are the relevant authorities.

Screening (population level): No population-based newborn or carrier screening program exists for NSML; identification remains clinically/case-driven.

Prophylaxis: No specific prophylactic medications are indicated beyond standard cardiac surveillance-triggered management (e.g., beta-blockade once HCM is identified, per general HCM management guidelines).

14. Other Species / Natural Disease

No naturally-occurring NSML has been reported in non-human species in the literature surveyed — this is not a recognized veterinary/companion-animal disease (OMIA search not specifically performed but no indication of natural animal disease emerged from the mechanism-focused searches). All animal data relate to induced/engineered models (see Section 15) rather than spontaneously-occurring disease in other species. PTPN11 orthologs are broadly conserved across vertebrates (mouse Ptpn11, zebrafish ptpn11a/ptpn11b), supporting the strong cross-species conservation of the underlying RAS-MAPK signaling mechanism, but no natural disease phenocopy has been documented.

15. Model Organisms

Mouse models (genetic, knock-in): - Ptpn11^Y279C/+ knock-in mouse — the principal NSML mouse model, used in the Lauriol 2016 (PMID:27348588) and Marin 2011 (PMID:21339643) studies, recapitulating hypertrophic cardiomyopathy and enabling dissection of the developmental endocardial origin of cardiac hypertrophy and the mTOR-dependence of the phenotype (reversible with rapamycin). - Ptpn11^D61G/+ mouse — the classic-NS gain-of-function comparator model, used alongside the Y279C NSML model in the PZR studies (PMID:24865967) to directly contrast GOF-NS vs. dominant-negative-NSML mechanisms in the same experimental system. - Adipose-tissue-targeted studies of the NSML mutation (Tajan et al. 2014, PMID:25288766) demonstrated the leanness/metabolic-protection phenotype, illustrating how the same germline mutation produces organ-specific, sometimes opposing, physiological consequences (pathogenic in heart, "protective" in adipose tissue).

Zebrafish models: - Zebrafish carry two ptpn11 paralogs (ptpn11a, ptpn11b), both functionally relevant (PLOS ONE, PMC3988099), enabling developmental dissection of SHP2 function; D61G (NS) and A462T (NSML-equivalent) Shp2 zebrafish models have been used in the PZR-coordination studies (PMID:24865967) to study cardiac and hematopoietic phenotypes with the transparency/rapid-development advantages of the zebrafish system. - Zebrafish models have also been used more broadly to study Shp2-MAPK signaling in developmental contexts (e.g., fin-fold regeneration), providing mechanistic insight transferable to the RASopathy signaling framework even outside the cardiac-specific NSML literature.

Phenotype recapitulation: The mouse knock-in models successfully recapitulate the cardinal cardiac phenotype (hypertrophic cardiomyopathy) and have been sufficient to establish causal, cell-type-specific (endocardial), and pathway-specific (mTOR-dependent) mechanisms, and to demonstrate pharmacological reversibility — a strong translational validation. Recapitulation of the pigmentary (lentigines), growth (short stature), and neurodevelopmental phenotypes in mouse/zebrafish models is less well documented in the sources reviewed here and would need separate confirmation before being asserted as strongly validated.

Model limitations: As with most RASopathy models, full recapitulation of the human variable-expressivity pattern (why genetically identical mutations produce a spectrum of severity across human family members) is not achieved in inbred mouse models, which are typically more phenotypically uniform.

Applications: These models have directly enabled (1) mechanistic dissection of GOF-NS vs. dominant-negative-NSML divergence at the same locus, (2) identification of developmental (endocardial) origin of adult HCM, and (3) preclinical proof-of-concept for both mTOR-inhibitor (rapamycin) and, by extension via the broader RASopathy MEK-inhibitor literature, MEK-inhibitor (trametinib) therapeutic strategies now advancing to human clinical trials (NCT06555237).

Summary Table: Suggested Ontology Term Bindings for KB Curation

Key References (PMID-verified in this research)

1. Digilio MC, et al. Grouping of multiple-lentigines/LEOPARD and Noonan syndromes on the PTPN11 gene. Am J Hum Genet. 2002;71(2):389-394. PMID:12161596
2. Kontaridis MI, et al. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem. 2006;281(10):6785-6792. PMID:16377799
3. Pandit B, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39(8):1007-1012. PMID:17603483
4. Marin TM, et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest. 2011;121(3):1026-1043. PMID:21339643
5. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice. PMID:24865967
6. Tajan M, et al. LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity. PNAS. 2014;111(42):E4494-E4503. PMID:25288766
7. Lauriol J, et al. Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines. J Clin Invest. 2016;126(8):2989-3005. PMID:27348588
8. GeneReviews: Sarkozy A, Digilio MC, Zampino G, et al. Noonan Syndrome with Multiple Lentigines. NBK1383 (authoritative source for diagnostic criteria, frequencies, and management recommendations cited throughout).
9. Orphanet: Leopard syndrome, ORPHA:500. orpha.net/consor/cgi-bin/OC_Exp.php?Expert=500
10. OMIM #151100 (LEOPARD syndrome 1/PTPN11), #611554 (LEOPARD syndrome 2/RAF1), #613707 (LEOPARD syndrome 3/BRAF).

Note on evidence gaps: Population-based prevalence/incidence figures, NSML-specific quality-of-life instrument data, MAP2K1/BRAF variant-level detail (beyond "rare reported cases"), and precise quantified tumor-risk statistics specific to NSML (as opposed to the broader Noonan spectrum) were not found with high-confidence primary-source citations in this search and would need targeted follow-up (e.g., direct OMIM/Orphanet full-text review, ClinVar variant-level pull, and a dedicated PubMed search for NSML-specific malignancy cohort studies) before being asserted as curated facts in a knowledge-base entry.